Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506289 | 0.88 | F10 (0.52) | F10GPR119CYP11B2DHODHTP53 | |
| SCHEMBL6494664 | 0.84 | GPR119 (0.41) | F10GPR119CYP11B2DHODHTP53 | |
| SCHEMBL5625864 | 0.77 | CYP11B2 (0.41) | GPR119CYP11B2DHODHMPO | |
| SCHEMBL30681413 | 0.74 | GPR119 (0.49) | GPR119CYP11B2DHODHTP53MPO | |
| SCHEMBL1998284 | 0.73 | F10 (0.43) | F10GPR119CYP11B2DHODHMPO | |
| SCHEMBL30681471 | 0.72 | DRD3 (0.46) | GPR119DHODHGAA | |
| SCHEMBL24557404 | 0.71 | GPR119 (0.69) | GPR119 | |
| SCHEMBL5389996 | 0.69 | NOTUM (0.68) | GPR119CYP11B2 | |
| SCHEMBL8257530 | 0.69 | HTR6 (0.46) | GPR119DHODHMPO | |
| SCHEMBL28429340 | 0.69 | GPR119 (0.45) | GPR119DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | F10 2/4885GPR119 3600/4885CYP11B2 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.